BRIEF RESEARCH REPORT article
Front. Oncol.
Sec. Gynecological Oncology
This article is part of the Research TopicPrecision Medicine and Targeted Therapies in Gastrointestinal and Genitourinary Solid TumorsView all 29 articles
Treatment with Mirvetuximab-Soravtansin – First clinical experience in advanced ovarian cancer in Comprehensive Cancer Center
Provisionally accepted
- 1Department of Obstetrics and Gynecology, Medical Center – University of Freiburg, Faculty of Medicine, Germany, Freiburg, Germany
- 2Department of Diagnostic and Interventional Radiology, Medical Center – University of Freiburg, Faculty of Medicine, Germany., Freiburg, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Mirvetuximab-Soravtansin (MIRV) is an antibody-drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor α (FRα)- expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome and adverse events. Methods: This retrospective single-center cohort study included 6 patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC-IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FRα ≥75% (IHC PS2+), and progression during systemic therapy with ≥ 3 therapies before. All Patients underwent ophthalmological examination before therapy with MIRV. Results: After 2-6 cycles of MIRV (median 3.3), objective descriptive response with CT-scan thorax-abdomen and CA-125 response were monitored. CA‑125 decreased in all evaluable patients (n = 5) from baseline. In the CT-scan, two patients showed radiographically stable disease, and one of our patients represented progressive disease. Two patients revealed a partial response, one of them had partial remission at the initial FIGO stage IV. Adverse events were monitored; one patient developed transient ocular toxicity. Discussion: Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.
Keywords: Advanced ovarian cancer, Folate receptor α (FRα), Mirvetuximab-Soravtansin, Ocular toxicity, platinum-resistant
Received: 25 Oct 2025; Accepted: 28 Jan 2026.
Copyright: © 2026 Schwörer, Huwer, Rautenberg, Neubauer, Juhasz-Böss and Jung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Isabella Flora Schwörer
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.